Stuart Curbishley

Stuart was awarded his PhD by the University of Birmingham in 2005 after which his group developed a programme of immune based therapies for liver disease and liver cancer.  He has undertaken a variety of first-in-man early phase clinical trials, leading the development of dendritic cell therapy for primary liver cancer in Birmingham.  Stuart now directs the University of Birmingham’s GMP manufacturing unit, overseeing the development of new ATMPs, within the University of Birmingham and in collaboration with UK and international organisations.  He supported the University of Birmingham, in partnership with other Midlands institutions and NHS Wales, forming one of three specialist Advanced Therapy Treatment Centres.  Stuart continues to grow the portfolio of ATMPs manufactured at in Birmingham, extending to T cell products, stromal cells, chondrocytes, and dendritic cells and brings his expertise in closing manufacturing processes and developing sustainable, scalable solutions to the projects his team work on.